The roles IGF of family in renal cell carcinoma

IGF家族在肾细胞癌中的作用

• 批准号: 14571501
• 负责人: KANAYAMA Hiro-omi
• 金额: $ 1.66万
• 依托单位: The University of Tokushima
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2002
• 资助国家: 日本
• 起止时间: 2002 至 2003
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/en/grant/KAKENHI-PROJECT-14571501/
• 关键词: Renal cell carcinoma; IGF family; microarray; ELISA; Insulin-like growth factor; IGFBP3; 免疫染色

It is reported that Insulin-like growth factor (IGF) system participates in growth and differentiation of both some normal cells and cancer cells. Generally, IGFs (IGF-I, IGF-II), type I and II IGF receptors, IGF-binding proteins (IGFBPs., and IGFBP proteases are contained in IGF system, and act as a mitogenic factor by combining IGF with type I and II IGF receptors or insulin-receptor. We-created gene profiling using the cDNA microarray, and we found that IGFBP3 and insulin receptor of IGF family highly expressed in renal cell carcinoma. We compared expression level of IGF family in the normal renal parenchyma with that in renal cell carcinama using RNase protein assay (RPA), and we estimated prognosis significance. As a result of inquiring by total of 13 genes, such as IGF1; 16F2, type I and II IGF receptors, H19 and ALS, insulin receptor, and IGFBP 1-6, strong expression was found in 100% of IGFBP3, 42% of insulin receptor, and 42% of IGFBP1 in 12 patients with renal cell Carcinoma. Furthermore, as a result of examining the expression level in the serum of such protein, IGFBP3 was intentionally high at the renal cell carcinoma patient. In the average of 17 months follow-up, a significant difference was not found as the prognosis factor, but further long-term follow-up was required. It was thought that measurement of IGF family was useful to diagnosis, and might become the target gene of renal cell carcinoma for gene therapy.

胰岛素样生长因子（IGF）系统参与了正常细胞和肿瘤细胞的生长和分化。通常，IGF（IGF-I、IGF-II）、I型和II型IGF受体、IGF结合蛋白（IGFBPs.和IGFBP蛋白酶包含在IGF系统中，并通过将IGF与I型和II型IGF受体或胰岛素受体结合而作为促有丝分裂因子。我们利用基因芯片建立了基因表达谱，发现IGF家族的IGFBP 3和胰岛素受体在肾细胞癌中高表达。采用RNA酶蛋白分析法（RPA）比较IGF家族在正常肾组织和肾癌组织中的表达水平，并评估其预后意义。通过对IGF 1、1 - 6 F2、I型和II型IGF受体、H19和ALS、胰岛素受体、IGFBP 1-6等共13个基因的查询结果，在12例肾细胞癌患者中发现IGFBP 3 100%强表达，胰岛素受体42%强表达，IGFBP 1 42%强表达。此外，作为检查这种蛋白质在血清中的表达水平的结果，IGFBP 3在肾细胞癌患者中故意高。在平均17个月的随访中，未发现作为预后因素的显著差异，但需要进一步长期随访。认为IGF家族的检测有助于肾癌的诊断，并有可能成为肾癌基因治疗的靶基因。

项目成果

Chen J., Lui WO., Vos MD., Clark GJ., Takahashi M., Schoumans J., Khoo SK., Petillo D., LeveryT., Sugimura J., Astuti D., Zhang C., Kagawa S., Maher ER., Larsson C., Albert AS., Kanayama HO., Teh BT.: "The t(1;3) breakpoint-spanning genes LSAMP and NORE1

Chen J.、Lui WO.、Vos MD.、Clark GJ.、Takahashi M.、Schoumans J.、Khoo SK.、Petillo D.、LeveryT.、Sugimura J.、Astuti D.、Zhang C.、Kakawa S.

Takahashi M: "Prognostic significance of matrix metalloproteinases-2 activation retio in renal cell carcinoma"Int J Urology. 9. 531-538 (2002)

Takahashi M：“肾细胞癌中基质金属蛋白酶-2 激活蛋白的预后意义”Int J Urology。

Takahashi M: "Prognostic significance of matrix metalloproteinases-2 activation retio in renal cell carcinoma."Int J Urol. 9. 531-538 (2002)

Takahashi M：“肾细胞癌中基质金属蛋白酶-2 激活蛋白的预后意义。”Int J Urol。

Nishitani M., Sakai T., Ishii K., Zhang M., Nakano Y., Nitta Y., Miyazaki J., Kanayama H., Kagawa S., Himeno K.: "A convenient cancer vaccine therapy with in viva transfer of Interleukin 12 expression plasmid using gene gun technology after priming with i

Nishitani M.、Sakai T.、Ishii K.、Zhang M.、Nakano Y.、Nitta Y.、Miyazaki J.、Kanayama H.、Kakawa S.、Himeno K.：“一种方便的体内转移癌症疫苗疗法

Takahashi M., Oka N., Naroda T., Nishitani MA., Kanda K., Kanayama HO., Kagawa S.: "Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma."Int J Urol.. 9. 531-538 (2002)

Takahashi M.、Oka N.、Naroda T.、Nishitani MA.、Kanda K.、Kanayama HO.、Kakawa S.：“肾细胞癌中基质金属蛋白酶 2 激活比率的预后意义。”Int J Urol.. 9